21 August 2023



ASX: EIQ RELEASE

ECHO IQ ANNOUNCES SIGNIFICANT EXPANSION OF ECHOSOLV[™] SOLUTIONS SUITE

Highlights:

- Six new cardiac decision-support solutions to be introduced between November 2023 & January 2024.
- Product expansion will significantly increase EchoSolv[™]'s addressable market.
- EchoSolv[™] platform advances towards delivering a "total heart solution" for 8 cardiovascular diseases and diagnostic indicators.
- Separately, new revenue-generating Software as a Solution (SaaS) contracts for EchoSolv[™]'s current modules are pending.

Sydney: Artificial Intelligence and Medical Technology company Echo IQ Limited ("the Company") (ASX:EIQ) is pleased to announce a significant expansion to EchoSolv[™]'s cardiology decision-support platform. The Company will be rolling out six new solutions between November 2023 and January 2024 designed to support cardiologists in accurately diagnosing and assessing:

1. Diastolic Dysfunction

This is a common heart problem, affecting the ability of the heart to relax and strongly related to some forms of heart failure. Getting an accurate diagnosis is important because diastolic dysfunction is associated with an increased risk of death. Diastolic dysfunction is more common in older individuals, and with high blood pressure, kidney disease, diabetes, heart valve diseases and heart failure, and diagnosis requires echocardiography (heart ultrasound). It can be difficult to diagnose¹ and is well suited to automated diagnosis using the EchoSolv[™] to assist doctors make this diagnosis.

2. Heart Failure

Heart Failure is the world's leading cause of hospitalisation and is estimated to affect more than 64 million people worldwide². Heart failure most commonly presents with breathlessness on exertion, but diagnosis can be difficult with many individuals only receiving the diagnosis late in the disease process. Treatments for heart failure are effective and can save many lives, and starting treatment early is important. The use of echocardiography is essential in the diagnosis of heart failure, and the EchoSolv[™] platform has allowed automation of diagnosis of heart failure to assist clinicians.



ECHOIQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 404/309 George Street, Sydney NSW 2000 Australia

3. Hypertension

Pulmonary Hypertension ("PH") is increased pressure of blood going from the right heart and into the lungs. PH is common³ in people undergoing echocardiography, and is associated with a high risk of mortality if left untreated⁴. The most common cause of PH is disease of the left side of the heart³, and most forms of PH can be treated successfully if the diagnosis is made early in the disease process. A timely diagnosis of PH is therefore of paramount importance and is well suited to automation using the EchoSolv[™] system.

4. Left Atrial Volume

The left atrial volume, usually indexed for body size, is a powerful marker of increased mortality and risk of stroke^{5,6}. Measurement of left atrial volume is routine in echocardiography, but application of clinical practice guidelines is not routinely undertaken. The EchoSolv[™] system allows consistent application of guidelines.

5. Left Ventricular Mass

The left ventricular mass indicates how much muscle is present in the left ventricle. It is an important marker of left heart diseases and is associated with risk of death if abnormally increased. The EchoSolv[™] system automatically presents and categorises the left ventricular mass according to risk groups and assists the clinician in reporting.

6. Mitral Stenosis

Mitral stenosis is the most prevalent heart valve disease in developing nations, and is the most common manifestation of rheumatic heart disease⁷. Although it is less common in developed nations, it is an important diagnosis in all regions and can be treated by valve intervention and/or replacement. The EchoSolv[™] system allows accurate diagnosis of severity to be presented back to the clinical to assist in reporting.

EchoSolv currently gives users decision-support for Aortic Stenosis and Mitral Regurgitation. Commencing November this year, these additional new modules will give users the benefit of easy-to-use, accessible decision-support tools for up to 8 cardiac conditions and indicators (at additional cost). With cardiovascular disease being the world's leading cause of death, this expanded solutions suite increases Echo IQ's addressable market in the world's most important healthcare sector. These solutions incorporate standard diagnostic guidelines and are designed to help doctors male more accurate assessments, more often.

Echo IQ Chief Medical Advisor, Professor David Playford said: "We are firmly committed to harnessing new technologies and applying them to the complex world of echocardiography. These new enhancements to the EchoSolv[™] platform simplify challenging diagnoses, and present them to doctors providing even greater levels of decision-support. Having EchoSolv[™] as the go-to decision support system will improve a doctor's accuracy of diagnosis and increase confidence to initiate life-saving interventions. It is another important step toward EchoSolv[™]'s whole-of-heart solution."



ECHOIQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 404/309 George Street, Sydney NSW 2000 Australia **Echo IQ Executive Chair Andrew Grover added:** "With these new extensions to EchoSolvTM, we are broadening the commercial application for this already impressive AI-driven platform. The new conditions and indicators we are integrating into the platform increase EchoSolvTM's utility and value for customers in this large and growing healthcare sector. Based principally on current industry diagnostic guidelines, these new modules fall outside the scope of FDA regulation which allows us to fast-track their introduction to the market.

"We are also pleased to confirm that our commercial pipeline for EchoSolv[™]'s current SaaS offering continues to build very favourably and we anticipate adding new revenue-generating contracts with hospitals and cardiologists in the near-term. There are a number of avenues to build the revenue base beyond SaaS deployments and a number of exciting opportunities continue to advance in this regard too."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries: Philip Woolff, Chief Operating Officer <u>philip.woolff@echoiq.ai</u> / <u>marketing@echoiq.ai</u> / +61 (0)490 030 620

Investor Enquiries: Andrew Grover, Executive Chair Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses Al-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

References:

- 1. Playford D, Strange G, Celermajer DS, Evans G, Scalia GM, Stewart S, Prior D. Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA). *European Heart Journal - Cardiovascular Imaging*. 2020. doi: 10.1093/ehjci/jeaa253
- 2. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145. doi: 10.1161/cir.000000000000000063
- 3. Strange G, Playford D, Stewart S, Deague JA, Nelson H, Kent A, Gabbay E. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. *Heart (British Cardiac Society)*. 2012;98:1805-1811. doi: 10.1136/heartjnl-2012-301992
- 4. Strange G, Stewart S, Celermajer DS, Prior D, Scalia GM, Marwick TH, Gabbay E, Ilton M, Joseph M, Codde J, et al. Threshold of Pulmonary Hypertension Associated With Increased Mortality. J Am Coll Cardiol. 2019;73:2660-2672. doi: 10.1016/j.jacc.2019.03.482
- 5. Biteker M, Kayataş K, Başaran Ö, Dogan V, Özlek E, Özlek B. The Role of Left Atrial Volume Index in Patients with a First-ever Acute Ischemic Stroke. *Journal Of Stroke And Cerebrovascular Diseases: The Official Journal Of National Stroke Association*. 2017;26:321-326. doi: 10.1016/j.jstrokecerebrovasdis.2016.09.023
- 6. Tsang TSM, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *The American Journal of Cardiology*. 2002;90:1284-1289. doi: https://doi.org/10.1016/S0002-9149(02)02864-3
- 7. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143:e72-e227. doi: doi:10.1161/CIR.00000000000923

Ai with heart

ECHOIQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 404/309 George Street, Sydney NSW 2000 Australia